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Abstract
Protein kinases are enzymes that transfer a phosphate group to the threonine,
serine, or tyrosine residues of the target protein, regulating its activity. The activity
of these enzymes are very important and strictly regulated in the cell as they
promote cell proliferation, survival, and migration. In the case of any dysregulation
of these enzymes, they can be associated with cancer initiation and progression.
Small-molecule kinase inhibitors approved by the FDA for their improved clinical
benefits are currently used in targeted therapy for the treatment of various cancers.
So far, there are 62 FDA-approved therapeutic agents targeting different protein
kinases, eight of which were approved in 2020. Today, kinase inhibitors are used as
FDA approved cancer agents and newly developed ones are evaluated in clinical
trials. Those protein kinase inhibitors can be grouped as growth factor receptor
inhibitors, Ras/Raf/Mek inhibitors, phosphoinositide 3-kinase (PI3K) and cyclin
dependent kinase inhibitors, other targets, and agents such as protein kinase c and 3
phosphoinositide-dependent kinase 1. In this chapter, these kinases, their pathways,
and their inhibitors will be discussed in detail.
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1. Introduction
Protein kinases (PKs) are enzymes that regulate the activity of a protein by
adding phosphate group to specific amino acids using ATP as a resource, thereby
resulting in a conformational change of that protein. More specifically, they add
terminal γ-phosphate group to the serine, threonine or tyrosine residues of the
target proteins and this process is called phosphorylation. Phosphorylation of a
protein changes its activity, location or downstream function that can result in
amplification of the first signal [1]. Furthermore, phosphorylation can also alter
biological activities such as transcription and translation. In addition, it can have
inhibitory or stimulatory effect on the target. In either case, it has a significant role
in regulation of cellular activities.
PK family is one of the largest protein family comprising more than 500 different
kinases in the human proteome that is encoded by 2% of the human genome [2]. PKs
in regulating protein activity have a massive effect on cell signaling pathways involved
in metabolism, immune responses, growth, differentiation, migration, and adaptation.
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Because of the potency of PKs, changes in their expression levels or patterns can
impact various pathways resulting in disease development including cancers, as
well as metabolic and developmental disorders.
PKs are tightly regulated to restrain their potency and any dysregulation could
result in a diseased state. Either a kinase itself or the pathway that the kinase is
regulated is mutated in many cancers [3–5] and those PKs can be classified as proto-
oncogenes. In fact, in 1978, the first identified proto-oncogene encodes a tyrosine
kinase called c-Src [6]. Overexpression or dysregulation of oncogenic kinases results
in altered signaling pathways and oncogenic transformation. In other words, any
perturbation on the regulation of oncogenic kinases can result in anchorage-
independent uncontrolled growth and proliferation as well as angiogenesis and
metastasis. Exploring the role of kinases in cancer development and progression
have highlighted the potential of kinase targeted therapies. In this chapter, we will
focus on the kinases’ role in oncogenic pathways and the kinase inhibitors targeting
these pathways as a therapeutic option.
Protein kinase inhibitors (PKIs) are antineoplastic substances that are used to
block the constant or overactivity of dysregulated protein kinases. The first devel-
oped PKI called imatinib mesylate (Gleevec, STI571, or CP57148B) targets a fusion
protein called “BCR-ABL” which is a constantly active tyrosine kinase that is
observed in chronic myeloid leukemia (CML). In addition, imatinib directly inhibits
ARG, KIT, and PDGFR tyrosine kinases and used to treat blood neoplasia other than
CML and solid tumors that stem from activation of these tyrosine kinases. Conse-
quently, the remarkable success of imatinib had a major impact on researchers to
focus on the development of other targeted PKIs that could be potential cancer
therapeutics. Following imatinib, other BCL-ABL inhibitors such as nilotinib,
dasatinib, bosutinib and ponatinib were developed to overcome imatinib-resistant
mutants [7].
The success of imatinib had opened the door to exploration of other oncogenic
kinases in other signaling pathways. Those kinase inhibitors can be grouped as
growth factor receptor inhibitors, Ras/Raf/Mek inhibitors, phosphoinositide
3-kinase (PI3K) and cyclin dependent kinase inhibitors, other targets and agents
such as protein kinase c and 3 phosphoinositide-dependent kinase 1 (PDK1). This
chapter will focus on the kinases’ role in oncogenic pathways and the kinase
inhibitors targeting these pathways as a therapeutic option.
2. Growth factor receptors
Development, growth and homeostasis of multicellular organisms are controlled
by growth factors. Growth factors show their activity by binding to their receptors
and are required for cell–cell communications for embryonic tissue induction, cell
survival, fate determination, apoptosis, cell migration and tissue specialization.
These receptors transmit extracellular signals to the intracellular region in two
ways: activation of intracellular transporters or direct translocation of the receptor
to the nucleus [8].
The feature of cancer is its continuous growth. Growth factors include epidermal
growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth
factor (FGF), transforming growth factor (TGF), insulin-like growth factor (IGF)
and platelet-derived growth factor (PDGF) and they stimulate proliferation,
migration and invasion of cancer cell and stromal cell, thereby regulating tumor
growth, angiogenesis and metastasis (Figure 1) [9]. Table 1 shows molecules that
inhibits growth factor receptors.
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2.1 Epidermal growth factor receptor
One of the most studied drugs in human cancer is the EGF family of receptor
tyrosine kinases (RTKs), also called ErbB or HER receptors [8]. Family of EGF
receptor (EGFR) comprises four receptor proteins: ErbB-1/EGFR-1 to 4 (also
called HER 1–4). These proteins are expressed on cell surface and have alike struc-
ture: an intracellular domain with kinase activity, a transmembrane domain and an
extracellular domain with ligand binding site [10]. The binding of EGFR ligand
initiates homo- and heterodimers between receptors, activating cascades of
mitogenic and anti-apoptotic signal [11].
The dimerization is required to activate the intracellular tyrosine kinase domain
and C-terminal tail phosphorylation. Its autophosphorylation then promotes either
directly or by adaptor proteins, the signal transduction pathways including
Ras/MAPK, PI(3)kinase/Akt, PLCg1/PKC, and STAT pathways [8] in modulating
differentiation, cellular proliferation, and survival [11].
EGFR has been extensively studied for cancer therapeutics due to mutations,
deletions, and overexpression in tumors [11]. EGFR is generally investigated in non-
small cell lung cancer (NSCLC): its amplification is 80% and its mutation is 20%
[12, 13]. When compared to chemotherapy used in NSCLC patients, EGFR TKIs have
more than twice the progression-free survival (PFS) with actionable mutations of
EGFR. Moreover, they have better objective response rates (ORRs), response time,
life quality, and reduction in treatment- associated toxicity [14]. First generation
EGFR-tyrosine kinase inhibitors (TKIs) bind reversibly to EGFR and block ATP-TK
domain binding and this blockage causes cell death by inhibiting cell proliferation
[15]. Some examples of these EGFR-TKIs are gefitinib, erlotinib, and icotinib [14].
When looked at the second-generation EGFR-TKIs these irreversibly bind to EGFR.
Afatinib and dacomitinib can be given examples as second generation [14]. Although
dacomitinib has improved median PFS, hazard ratio, and median overall survival
[16, 17] compared to first-line treatment, the usage of afatinib and dacomitinib in
clinical practice may be limited due to having increased toxicities [18].
EGFR T790M mutation causes almost 50% resistance to EGFR-TKIs of first and
second generations [19]. As an EGFR TKI of third-generation, osimertinib inhibits
Figure 1.
Kinase inhibitors and their inhibition pathways. Cetuximab binds to EGFR with a higher affinity than EGF
and competitively inhibits its binding. Other drugs compete with ATP, inhibits the autophosphorylation process.
1st generation EGFR inhibitors gefitinib, erlotinib and icotinib are not effective against the receptors containing
exon 19 deletion and L858R mutations. On the other hand, 3rd generation drug osimertinib is effective against
EGFR containing exon 19 deletion, L858R and T790M mutations. Bevacizumab binds to VEGFR ligand
VEGF, inhibiting its binding with VEGFR. Other inhibitors of VEGFR, FGFR, IGF-R1 and PDGFR target
autophosphorylation mechanism, thereby prohibiting the downstream activation of other proteins.
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both EGFR T790M mutations and EGFR-sensitizing [20] and it is promising for
central nervous system (CNS) metastatic patients which is due to EGFR mutation in
NSCLC patients [20] or after treatment with EGFR-TKIs of first- or second-
generation [21]. Other EGFR TKIs as a third-generation for advanced NSCLC with
mutation in EGFR T790M are almonertinib [22], furmonertinib (AST2818) [23],
BPI-7711 [24], lazertinib (YH25448) [25], and nazartinib (EGF816) [26], and they
have exhibited acceptable safeties and promising efficacies. Almonertinib was also
approved by China National Medical Products Administration (NMPA).
Monoclonal antibodies (mAbs), cetuximab and panitumumab, have been used
against EGFR and are approved for metastatic colorectal cancer (CRC) treatment.
Only small patient subgroups to cetuximab and panitumumab indicate clinical
benefit. The best response to cetuximab and panitumumab is seen in patients with
the combination of wild type KRAS, BRAF, and PIK3CA and PTEN protein express
[27]. Trastuzumab is another mAb used in EGFR/HER2 pathway for the treatment
of HER2-positive breast cancers [28].
2.2 Vascular endothelial growth factor receptor
Vascular endothelial growth factors (VEGF) are a family of polypeptides contain
highly conserved receptor binding domain in disulfide-node [29]. There are two
Target Inhibitors
FGFR Futibatinib Infigratinib Erdafitinib
TGF-βR Galunisertib LY2109761
IGFR Linsitinib Picropodophyllin (AXL1717)
PDGFR Famitinib Cediranib
Table 1.
Structures of growth factor receptors inhibitors.
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types of VEGF; VEGF-A and VEGF-B, which bind their receptors named RTK.
VEGF members display plural interactions with RTKs are the critical factors for
blood vessel formation which cause cord formation and tubulogenesis, differentia-
tion of endothelial cells, proliferation, migration. In mammals, the vascular endo-
thelial growth factor receptor (VEGFR), transmembrane tyrosine kinase receptors,
comprises three members VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3
(Flt-4), and control the generation of blood and lymphatic vessels [30].
VEGFRs have seven immunoglobulin (Ig)-like domains on the extracellular site
and two split tyrosine kinase domains in the intracellular site [10]. In adults, while
the vascular endothelial cells are posess largely VEGFR-1 and VEGFR-2 in their
structure, the lymphatic endothelial cells have VEGFR-3 [31]. The literature shows
that VEGF pathway is critical for renal cell carcinoma (RCC) initiation and pro-
gression, and VEGFRs targeted TKIs have been used for most favorable RCC
treatment strategy.
In recent years, VEGFR-associated multi-targeted TKIs have been revealed as
antı-tumor agents for cancer treatment [18]. VEGFR-targeted therapeutic agents
have become the main element used for RCC patients treatment [31]. The FDA has
approved 6 small molecules, named as sunitinib, sorafenib, axitinib, pazopanib,
cabozantinib and lenvatinib, that inhibit VEGFR1/2/3 for use in RCC treatment.
Additionally, for clinical trials, seven VEGFR inhibitors; vandetanib, vorolanib,
anlotinib, MGCD516, regorafenib, tivozanib, and apatinib are under review [31].
Not only VEGFRs targeted and block by these drugs, also some other receptors
generally overexpressed in RCC, platelet-derived growth factor (PDGF) receptors a
and b (PDGFR-a/b), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3
(FLT3), tyrosine protein kinase MET, rearranged during transfection (RET), tyro-
sine kinase that contains immunoglobulin-like loops and epidermal growth factor-
similar domains-2 (Tie2), fibroblast growth factor receptor (FGFR), the GAS6
receptor (AXL), serine/threonine protein kinase Raf-1, colony stimulating factor1
receptor (CSF1R), and discoidin domain receptor (DDR) targeted by these small
drugs. In addition, growth, proliferation and angiogenesis of tumor cells are signif-
icantly inhibited by the effects of VEGFR1/2/3 inhibitors. The humanized IgG1
monoclonal antibody approved in 2009, Bevacizumab can bind VEGF and for use in
first-line therapy for RCC in combination with IFN-α [32].
Besides, in hepatocellular carcinoma (HCC), the efficiency of VEGFR-associated
multi-targeted TKIs was demonstrated. Especially Sorafenib can target VEGFR,
PDGFR, FGFR, and other signaling targets and prefered as first line therapy in
inoperable cases [33, 34]. In phase II/III studies of Donafenib, VEGFR-associated
multitargeted TKI, is shown a higher overall survival rate than sorafenib in
advanced HCC cases [35]. Moreover, regorafenib [36], apatinib [37] and
cabozantinib [38] are used for second-line treatment of HCC. More recently, it is
shown that Pembrolizumab is anti programmed cell death protein-1 (PD-1) anti-
body and lenvatinib combination therapies demonstrated promising anti-tumor
effect on untreated/inoperable HCC patients and this combination named as
breakthrıough therapy by FDA [39].
For lung cancer therapy (on NSCLC [40] and SCLC [41]), Anlotinib showed
promising results and was approved for further-line therapy by(National Medical
Products Administration of China (NMPA) [18]. Furthermore, similar results
identified in thyroid carcinoma and soft tissue sarcoma (STS) patients [42].
2.3 Fibroblast growth factor receptor
Fibroblast growth factor receptors (FGFRs), which are members of receptor
tyrosine kinase can be thought as single pass membrane proteins due to the cellular
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membrane covering in a single region [43]. There are four transmembrane proteins
(FGFR1–4) for the FGFR family and different isoforms of them with changed
ligand specificity [10]. Upon binding of the different FGF ligands to different FGF
receptors, auto-phosphorylation and kinase activation are initiated by FGFR
dimerization. This binding causes cell death inhibition and uncontrolled growth,
respectively due to downstream anti-apoptotic PI3K/AKT signals and mitogenic
growth signals (MAPK) so the interaction FGF-FGFR plays a critical role in tumor-
igenesis. Moreover, the downstream of PLC/PKC pathway joins the MAPK pathway
to promote cell growth [10].
The use of FGFR pathway downstream molecules as targets in anti-cancer drugs
has attracted attention, and these drugs are small compounds and antibodies against
cancer driver mutations in FGFRs and related signaling molecules [43]. Most FGFR-
TKIs belong to multiple target TKIs [18].
FGFR2 changes are associated with the cholangiocarcinoma (CCA).
Pemigatinib, a FGFR1–3 TKI, has been accepted for the treatment of locally
advanced or metastatic CCA [44]. Some other FGFR-TKIs (such as futibatinib,
infigratinib) also have the potential to be used for CCA based on their results [45].
In addition to CCA, FGFR2 changes also play a role in urothelial carcinoma
(UC). Fusions and mutations in FGFR2/3 are seen in 20% of patients with UC [46].
Treatment with erdafitinib, a FGFR1–4 TKI, has been accepted for the adult
patients with previously treated metastatic or locally advanced FGFR2/3-mutated
UC. Response was more promising as second-line therapy for advanced UC com-
pared to antibody-drug conjugates such as enfortumab vedotin or sacituzumab
govitecan [47] and pembrolizumab [48]. In addition, other inhibitors of pan-FGFR
are investigated and for example infigratinib (BGJ 398) is examined in the
treatment of UC holding a FGFR3 mutation [47].
2.4 Transforming growth factor-β receptor
Transforming growth factor-beta (TGF-β) is a cytokine which has different
functions and modulates cell growth and differentiation, extracellular matrix pro-
duction, apoptosis, angiogenesis, cell motility, and cellular immune responses.
Interestingly, TGF- β shows different effects on tumorigenesis. Although it acts as a
tumor suppressor in the early stages, it advances tumor growth by producing a
more suitable environment for tumor invasion and metastasis in later stages [49].
There are three membrane receptors for the TGF-β receptor (TGF-βR) family:
TβRI, TβRII and TβRIII. Their expression in various cell types control different
cellular functions by altering signals upon ligand binding of TGF-β [10]. When high
binding affinity is established between activated TGF-β and TβRII signaling is
started. The binding needs altering the conformation of TβRII by engagement of
TβRIII [49]. Receptors transphosphorylation is triggered after binding is created
between TGF-β ligand and transmembrane receptor serine/threonine kinase (type I
and II) complex. After that, SMAD proteins in C-terminal serine are phosphory-
lated by activated receptors. SMAD complexes which are activated control target
genes transcription by migrating to the nucleus [50], thereby controlling cell pro-
liferation, migration, survival, and differentiation [10].
TGF-β can signal via intracellular Smad proteins and some Smad independent
pathways involving ERK, MAP kinase, PI3K, JNK, p38, and AKT [49]. The Smad
pathway is very important in the antiproliferative properties of TGF-β and modifi-
cations in the Smad system by missense mutations [51, 52]. Moreover, blocking of
the phosphorylation process or Smad 2/3 complex formation has been demonstrated
to be effective in tumor development [53]. The TGF-β overexpression has been
determined in many tumors containing cancers of the breast, colon, liver, stomach,
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lung, esophagus, kidney, prostate, pancreas, brain, and malignant melanoma,
as well as certain hematological malignancies [54–61]. Some small-molecule
TKIs of TβR II and TβR III can block the signaling pathway of TGF-β-mediated
receptor.
Galunisertib (LY2157299) monohydrate has shown powerful as a TβR I inhibitor
by reducing Smad2 phosphorylation in pancreatic, colorectal cancer, lung cancer
[62] and ovarian cancer [63]. LY2157299 is another promising inhibitor of Smad2
phosphorylation for hepatocellular carcinoma models [64]. It moved to Phase II and
was approved by the FDA for liver cancer as an orphan drug in 2013. LY2109761 for
metastatic NSCLC [65], colorectal cancer [66] could also investigated as a kinase
inhibitor. In addition, Ki26894 blocks Smad2 phosphorylation by binding to the
TβR I-ATP domain and its activity was demonstrated in breast cancer [67] and
gastric cancer [68].
2.5 Insuline-like growth factor receptor
The insulin-like growth factor receptor (IGFR) family includes two cell mem-
brane receptors, named as IGF-IR and IGF-IIR. IGF-IR (that also forms a
heterodimer with the insulin receptor [IR]) has higher affinity to insulin-like
growth factor 1 (IGF-I) but IGF-II comparatively has lower affinity. Although
IGF-IR, receptor tyrosine kinase, has the triggering effects on IGF-I and IGF-II and
thus on cell proliferation, migration and invasion, IGF-IIR lacks kinase activity [9].
Pathways activated by the presence of IGF and progressive pathological and
physiological processes take place through proper receptors, named as IGFR. The
mature IGF-IR have homodimer structure, containing α2 and β2 chains bounded
with disulfide bonds. The intracellular domain is autophosphorylated by the bind-
ing of ligands and the downstream processes continue with the activation of a
number of proteins. In several carcinomas, proliferation, transformation and
metastasis are induced by overexpression of IGFIR genes. IGF-IIR, called mannose-
6 phosphate receptor, M6P, is formed as a single polypeptide chain and performs as
a “scavenger receptor” that suppresses tumor growth, modulates invasiveness, and
blocks angiogenesis. Mutated IGFIIR locus could be found in lung cells and early
phase hepatocellular carcinoma [10].
Especially, cancer associated macrophages, tumor cells and liver cells secrete
IGF. The increased risk of breast and prostate cancer is correlated with high levels
of IGF in the circulating system [69, 70]. For smokers,there is a moderate correla-
tion between IGF level and lung cancer risk [71]. IGF-I is not related to colorectal
cancer but takes increased risk for colorectal cancer [72]. Multiple signaling path-
ways of PI3K/Akt, JAK/STAT, MAPK, Src and focal adhesion kinase (FAK) lead to
the proliferation, survival, and migration of cancer cells by binding IGF to its
appropriate receptor, are activated.
In many human tumors, especially mesenchymal, epithelial and hematopoietic
cancers, the growth of cancer cells, metastasis and the formation of drug resistance
can be associated with the activation of IGF signaling pathways [73–75].
The IGF-IR has been evaluated as a target protein in cancer treatment. There are
some small-molecule inhibitors and anti-IGF-IR mAbs used in pre-clinical models
and clinical trials. A dual IGF-IR/Insulin receptor inhibitor, linsitinib (OSI-906), is
investigated in phase II in recurrent small cell lung cancer patients. However,
clinical activity failed to show improvement in small cell lung cancer, metastatic or
advanced adrenocortical carcinoma, metastatic colorectal cancer, advanced NSLC,
gastrointestinal stromal tumors and metastatic prostate cancer. AXL1717 is studied
in early phase with relapsed malignant astrocytomas and can show long-term stable
disease and patients’ survival [9].
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2.6 Platelet derived growth factor receptor
Platelets produce platelet-derived growth factor (PDGF) and are secreted from
both epithelial and mesenchymal cells [76]. The PDGF family has five isoforms
(PDGF AA, BB, AB, CC, and DD) that bind to two RTKs, PDGFRα and PDGFRβ.
After activation of PDGFRα and β, they promote cell proliferation, migration and
survival through initiating signaling pathway with the inclusion of the extracellular
signal-regulated kinase 1/2 (ERK) and phosphatidylinositol 3-kinase (PI3K)/AKT [77].
Overexpressed platelet-derived growth factor receptor (PDGFR) is associated
with the formation of various human tumors like glioma, neurofibroma, ovarian
cancer, prostate cancer, and non-small cell lung carcinoma. In addition, PDGF
accelerates angiogenesis by increasing VEGF expression and development of
cancer-related fibroblasts that directly or indirectly affect tumor formation.
Moreover, PDGF plays a role in gene amplification [76].
To enhance anti-angiogenesis effect and suppress tumor growth PDGFR is
targeted by most VEGFR-related multiple kinase inhibitors such as sorafenib,
sunitinib, regorafenib, lenvatinib, axitinib, pazopanib, anlotinib, famitinib, donafenib
and cediranib. These inhibitors can be critical to treat various cancer types [18].
3. Ras/Raf/MEK pathway inhibitors
Ras/Raf/MEK pathway inhibitors are important as kinase inhibitors in various
cancer treatment. Firstly, the Ras protein known as Ras GTP-binding protein is the
member of small G protein family, which has an important role in transmitting
growth factor and relay signals from activated growth factor receptors (GFR)
(Figure 2).
Ras proteins are regulated by a GDP-GTP cycle, different form is carried out
when bound to GDP or GTP, inactive form is Ras-GDP and active form is Ras-GTP
[78]. Therefore this cycle has been stimulated via receptor activation then Ras
proteins bind to GTP (active form), cellular proliferation and other effects are
Figure 2.
Downstream molecular pathways that are activated upon stimulation of receptor tyrosine kinases (RTKs). The
main pathways include protein kinase C (PKC), Ras–Raf–Mek and PI3K pathways.
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promoted [79]. Ras protein associate with cell transformation such as cell growth,
differentiation, apoptosis, cell migration, this Ras regulation is carried out by mod-
ulating some signaling molecules by translocating them to the plasma membrane for
activation. Since Ras proteins play critical role as a branch point in signal
transduction and orchestrate the activity of multiple signaling pathways such as
Raf/MEK/ERK [78].
Numerous of the signal transduction pathways are occurred through protein
kinases regulating of cellular metabolism [80]. One of the most important key
protein kinases are Ras, Raf and MEK for targeting of the anticancer drug and also,
Ras mutations are quite common as they are identified in about 30% of cancers
[81–83]. Ras protein activations are depended on the cancer type, for instance
N-Ras in lymphoid and myeloid cancers, K-Ras in colon and pancreatic cancers,
H-Ras in bladder and kidney cancers [84]. One of the main reasons for this situation
is thought to be the disorder in protein kinase activity. Thus, the protein kinase
enzyme family is seen as one of the most important drug targets of the 21st century
in many diseases, especially cancer, and there are 62 FDA-approved therapeutic
agents targeting different protein kinases, eight of which were approved in 2020
[85]. Thus, today, kinase inhibitors are both used as FDA approved cancer agents
and evaluated in clinical trials. Protein kinase inhibitors related to the Ras / Raf /
MEK pathway, which is the subject of this part, are structurally classified as small
molecules and antisense oligonucleotides and structure of Ras/Raf/MEK kinase
inhibitors is shown in Table 2.
3.1 Ras kinase inhibitors
Ras protein, which has the ability to induce different growth and proliferation
pathways of the cell, is located in the cell membrane. And most importantly,
overactivation of mutated Ras can induce to make progress in cancer. Farnesyl Trans-
ferase enzyme catalyzes the first step of the reaction in the posttranslational modifi-
cation of both the normal and mutated Ras gene, thus it is easier to settle on the cell
membrane. FTase, one of the tansferase enzymes, targets Ras proteins, adding a
farnesyl group to it. After the essential transfer step, the activity of the Ras protein has
been inhibited by Ftase [86, 87]. Therefore, FTase enzyme and the downstream
pathways of the Ras protein are considered to be one of the most important groups of
targets that can be medicated in cancer therapy [88]. The potential anti-cancer agent
effect of Farnesyl Transferase inhibitors acting as kinase inhibitors which is affecting
Ras and Ras downstreamwill be reviewed in this part. Various FTase inhibitors such as
tipifarnib/R115777, lonafarnib/SCH66336, L-778123 and BMS-214662 have been used
primarily in clinical trials and phase studies [89].
The antitumor activity of tipifarnib, a potent and selective farnesyltransferase
inhibitor, also known as R115777, has been evaluated the antiproliferative effect of
tipifarnib, 53 human tumor cell lines have been studied and 75% were obtained to
be sensitive to R115777 [90, 91]. The strong potency effect of Tipifarnib was
detected in SU86.86 human pancreatic cells, CAPAN-2 human pancreatic cells and
NCI-H441 human lung cells and these cells espacially include the KRAS 12 mutation
cells [90, 91]. Tipifarnib has been studied as a phase 2 study on 249 adult patients
with refractory urothelial carcinoma (UC) and HRAS mutation. This study shows
that tipifarnib is effective in previously treated metastatic UC patients by inhibiting
the processing of newly synthesized proteins [92]. In refractory advanced colorectal
cancer as a Phase III study, it had an acceptable toxicity profile and was well
tolerated but did not improve overall survival according to the best supportive [93],
and R115777 was not effective in metastatic colorectal cancer patients in another
Phase II study [94]. Another phase two studies of R115777 emphazied that
10
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antitumor properties were not observed in metastatic c pancreatic cancer and did
not improve overall survival in advanced non-small cell lung cancer [95, 96].












CI-1040 Binimetinib (MEK162) PD 0325901
Cobimetinib (GDC-0973) Selumetinib (AZD6224) Trametinib (GSK1120212)
Table 2.
Structures of Ras–Raf–MEK kinase inhibitors.
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are thought to be effective in the Ras pathway, has being continuing to be evaluated
different combination therapies studies as well as single therapy [97].
Lonafarnib (SCH66336) as a clinical candidate FTase inhibitor, showed
antitumor activity in vivo lung, colon, pancreas, bladder and prostate human tumor
xenograft models [98]. Various antiproliferative effects of the SCH66336 agent
were observed in eight human astrocytoma cell lines with different concentrations
of IC50 values (0.6 mM - 32.3 mM) [99]. Growth inhibitory effects of the drug
SCH66336 were observed in human tumor xenografts with various tumor models
(colon, lung, pancreatic, prostatic carcinoma and a H-ras transgenic mouse model)
[100]. In the other phase 2 studies, Lonafarnib, which was used as a combined
treatment with paclitaxel, had clinical benefit and low toxicity in patients with non-
small cell lung carcinoma, while the targeted response of Lonafarnib was not
observed in 5-fluorouracil and irinotecan-resistant metastatic colorectal cancer and
gastrointestinal toxicity was observed in single therapy [97] .
L-778123, a peptidomimetic farnesyl protein transferase (FPTase) inhibitor, was
administered to patients with solid malignancies developed in phase 1 studies and
their toxicity levels were investigated. While unacceptable toxicity was observed at
the doses of L-778123 given as 1120 mg / m2 / day, the dose of 560 mg/m2/day was
well tolerated. Also, no objective tumor response was observed following drug
administration in this phase 1 study [101]. When the toxicity of L-778123 and
radiotherapy combination was evaluated in phase 1 studies, it was found to be at an
acceptable level in pancreatic cancer patients [102]. Although there are no impor-
tant studies on cancer treatment in phase 1, this drug has been stopped in its clinical
development due to its severe and unexpected toxicity [103].
3.2 Raf kinase inhibitors
Receptor tyrosine kinase effector Raf derives its name from “Rapidly Acceler-
ated Fibrosarcoma” [104]. There are 3 different isoforms of Raf family related to
serine/threonine protein kinases, namely Raf-1, A-Raf and B-Raf [105]. Critical
steps are needed for Raf activation to occur, these are Raf-1 phosphorylation,
binding of Raf protein to Ras-GTP, oligomerization of Raf protein, interaction of
Raf protein with membrane lipids, and conformational changes in Ras-induced Raf
protein [106]. Phosphorylation of Raf kinases plays an important role in cell cycle
regulation, proliferation and differentiation, cell survival, apoptosis, and many
cellular processes [107]. Furthermore, Raf kinase isoforms become overactive in a
variety of solid tumors such as renal cell carcinoma (RCC), hepatocellular carci-
noma (HCC), non-small cell lung cancer (NSCLC), and papillary thyroid carci-
noma. BAY 43–9006 is a potent Raf kinase inhibitor with significant activity in four
different types of human tumors, including colon, pancreatic, lung and ovarian
tumors. The in vivo study of BAY 43–9006 shows that after 14 days of injection,
tumor growth is strongly suppressed in athymic mice modeled with human tumors
[107]. It suggests that BAY 43–9006 may have clinical potential as a cancer thera-
peutic agent with a new mechanism of action with its antitumor activity [107]. One
of the other important raf kinase inhibitors is ISIS 5132 (CGP 69846A), for which
phase I and II studies have also been performed. This Raf kinase inhibitor provides
inhibition of c-Raf mRNA expression and inhibits the proliferation of lung, colon,
cervical, prostate and ovarian carcinoma cell lines [105]. According to the phase1
and phase 2 studies performed with ISIS 5132, no significant response occurred in
small cell or non-small cell lung carcinoma, hormone-resistant prostate cancer, and
Colorectal cancer [105]. There are two FDA approved molecules among Raf Kinase
Inhibitors, one of which is Dabrafenib (GSK2118436), which is effective in
BRAFV600E/K melanomas, BRAFV600E NSCLC, BRAFV600E anaplastic thyroid
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cancers, and Encorafenib (LGX818), which is suitable for combination therapy with
binimetinib for BRAFV600E/K melanomas [85].
3.3 MEK kinase inhibitors
One of the most important involved in cancer biology downstream targets of Ras
is mitogen activated extracellular signal regulated kinase (MEK) [108]. Various
MEK inhibitors, one of the first selective inhibitors of mitogen-activated protein
kinase (MAPK) pathway activation, were investigated in phase 1 and 2 studies
[109]. CI-1040, the first MEK inhibitor participating in the clinical study, was
tested on 66 patients, while a partial response was observed in one patient with
pancreatic cancer, stable disease was observed in 19 patients with various solid
tumors such as non-small cell lung, breast and colon cancer [110]. PD 0325901, a
second generation MEK inhibitor, was studied in 27 patients, while a partial
response was observed in two patients with melanoma, and stable disease was
observed in eight patients with various solid tumors [111]. There are 4 different
FDA approved small molecule protein kinase inhibitors, for which “MEK1/2” is the
primary target. These FDA approved MEK protein kinase inhibitors, Binimetinib
(MEK162), Cobimetinib (GDC-0973), Selumetinib (AZD6224), Trametinib
(GSK1120212), are respectively effective in these diseases; Combination therapy
with encorafenib for BRAFV600E/K melanomas, melanomas in combination with
vemurafenib, Neurofibromatosis type I, BRAFV600E/K melanomas, BRAFV600E
NSCLC [85].
4. Phosphoinositide 3-kinase (PI3K) pathway inhibitors
The activation of PI3K, a superfamily of lipid kinases, leads to the production of
lipid seconder molecule phosphatidylinositol-3,4,5-trisphosphate (PIP3) which
recruits phosphatidylinositide-dependent protein kinase (PDK1) and Akt protein
kinases to the plasma membrane. Akt that activated and phosphorylated from PDK1
and mTOR, phosphorylates several target proteins either at the plasma membrane
or in the cytosol and nucleus (Figure 2). Cell proliferation controlled by the PI3K
pathway is partially dependent on a large kinase protein called mammalian target of
rapamycin (mTOR). mTOR complex 1 plays a role in cell growth and survival by
stimulating nutrient uptake and metabolism. Akt activates mTOR independently of
phosphorylation at complex 1 [112].
PI3K has three different classes (I, II and III) and four different isoforms (α, β, γ, δ).
While it has central physiological roles in cancer, diabetes, and aging, the isoform
within each class has distinct roles.Several small molecules have been produced with
good pharmacological properties that have been tested in various cancers to selectively
inhibit PI3K, AKT or, mTOR [113].
Idelalisib and Copanlisip are FDA-approved drugs. Idelalisib has been selectively
developed for the delta isoform of PI3K p110 inhibitor. This purine-quinazoline
derivative has been used for the treatment of patients with CLL, relapsed follicular
B-cell non-Hodgkin lymphoma (NHL), and relapsed small lymphocytic leukemia
(SLL) [114]. The combination study with rituximab resulted in a significant
increase in the response rate and overall survival on CLL patients [115]. Copanlisip
is the inhibitor of the pan-class I PI3K, which shows preferential activity against
p110α and p110δ as compared with p110β and p110γ. It has been used for the
treatment of various subtypes of indolent and aggressive malignant lymphoma such
as NHL, relapsed follicular lymphoma (FL), and CLL in phase II study. This small
molecule, administered intravenously, becomes advantageous compared to other
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FDA-approved drugs, exhibiting a favorable toxicity profile and maintaining
efficacy [116].
Rapamycin and derivatives (CCI-779 and RAD001) inhibit both mTOR and the
downstream kinase target such as p70S6 kinase (p70S6K) and 4E-binding protein-1
(4E-BP1). The derivatives under clinical study have been shown to suppress the
proliferation and growth of various tumor cell lines by blocking the G1-S transition
in the cell cycle [117]. Furthermore, the immunosuppressant effect of rapamycin
has been observed in several case studies, with transplanted patients reducing the
incidence of cancer [118]. In ongoing clinical studies in prostate cancer in which the
PI3K/Akt/mTOR pathway is highly expressed, it was observed that rapamycin and
its derivatives were well tolerated in prostate cancer patients and decreased mTOR
level [119]. In addition to the antiproliferative effect, RAD001 is also used as an
immunosuppressant for the treatment of several malignancies in phase I study
[120]. CCI779 that is the soluble ester of rapamycin [121] has been used for the
treatment of several cancers in phase II study. This drug candidate has been used for
T-cell leukemia, prostate, breast, and SCLC, as well as glioma and melanoma cell
lines. CCI779 showed apoptosis induction, delaying the growth of the tumor,
encouraging survival [105]. In combined treatment with apatinib, the treatment
inhibits the proliferation and migration of small cell lung cancer cell lines [122].
Recently synthesized CYH33 is a novel PI3Kα inhibitor in phase 1b clinical trial
for esophageal squamous cell carcinoma (ESCC) and breast cancer therapy. In vitro
and in vivo studies show the anti-proliferative activity of this drug candidate to cell
lines, induction of G1 phase arrest, and down-regulation of phosphorylated ERK in
solid tumors [123]. The structure of all PI3K pathway inhibitors is shown in Table 3.
Target Inhibitors
PI3K Idelalisib Copanlisib Rapamycin
CCI-779z RAD001 CYH33
Table 3.
Structures of PI3K pathway inhibitors both in clinical development and FDA approved.
14
Protein Kinases - Promising Targets for Anticancer Drug Research
5. Cyclin-dependent kinase (CDK) inhibitors
CDKs found in a family of serine/threonine kinases are key regulators in the
various phases of the cell cycle (Figure 3). CDKs ensure the continuation of the cell
cycle by phosphorylating critical target proteins that are necessary to proceed to the
next stage. Especially cells need to regulate the phosphorylation of kinases to sustain
constant division in the presence of abnormal ploidy. Cyclin proteins, differently
from CDKs, are synthesized at certain stages of the cell cycle. When the various
cyclin form complexes with their target CDKs, it regulates the cell cycle transitions
by enabling them to be phosphorylated and activated. For example, both cyclin
D/CDK4 and cyclin D/CDK6 complexes direct phosphorylation of the Retinoblas-
toma gene (RB), which induces the separation of E2F to allow the transcription of
the genes necessary for the proceed G1 to S phase transition. CDK inhibitors have
been used in cancer therapy to interfere with the limitless replicative potential
which is one of the hallmarks of cancer cells [124].
Palbociclib (PD 0332991) [128], Ribociclib (LEE011) [125], and Abemaciclib
(LY2835219) [126] are novel dual inhibitors of both CDK4 and CKD6, that were
approved by the FDA. Abemaciclib, more potent against CDK4 (IC50s of 2 nM for
CDK4 and 10 nM for CDK6) [126]. These drugs have using for the treatment of
postmenopausal women with HR-positive, HER2-negative advanced, or metastatic
breast cancer. The action mechanism is that inhibiting the phosphorylation of Rb
protein in the G1 phase results in cell cycle arrest [127]. Palbociclib has a synergistic
effect in combination therapy with either letrozole or fulvestrant [128].
Abemaciclib also has a synergistic effect with gemcitabine [126].
BMS-387032 (SNS-032) is an aminothiazole, selectively designed for
CDKs 2, 7, and 9 (with IC50s of 38 nM, 62 nM, and 4 nM, respectively) inhibition.
Its activity was shown to inhibit both the cell cycle and the expression of anti-
apoptotic proteins in various carcinoma models [129]. A phase I dose-escalation
clinical trial study carried out to evaluate the safety, and clinical efficacy demon-
strates limited clinical activity in heavily pretreated CLL and MM patients [130].
CYC202 (Seliciclib) shows potent inhibitors for broad CDK such as Cdk2, Cdk1,
Cdk7, and Cdk9 (with IC50s of 0.1, 2.7, 0.5, and 0.8 mM, respectively), competing
at their ATP binding sites [131]. This small molecule showed antitumor activity
Figure 3.
Cyclin dependent kinases (CDKs) in the cell cycle and their inhibitors. CDKs are a family of serine/threonine
kinases and key regulators in the cell cycle.
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inducing apoptosis in multiple myeloma cell lines and has assayed in phase II study
resulted in the dosing schedule being tolerable in nasopharyngeal carcinoma
patients [132].
E7070 is a novel chloroindolyl-sulfonamide anticancer agent, which leads to
induces arrest at the G1-S boundary and in company with mitigation in the expres-
sion of CDK2. E7070 has been assayed for melanoma cancer therapy in phase II and
the results showed that CDK activity can be inhibited in tumor cells, but the dose
and schedule applied are not suitable for single-agent chemotherapy for melanoma
cancer treatment [133].
Flavopiridol has potent strong activity on several CDKs (CDK1, 2, 4, 6, and 7).
In addition to controlling the cell cycle, it exhibits more than one action mechanism
by showing an antiproliferative effect to leukemias and lymphoma cell lines
Target Inhibitors





Structures of CDK kinase inhibitors both in clinical development and FDA approved.
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[134, 135]. Phase I and phase II studies have been tested on various progressive
tumors and it has been observed that flavopiridol has no effect on metastatic renal
carcinoma [135]. The structure of all CDK kinase inhibitors is shown in Table 4.
6. Other protein kinase inhibitors
Protein kinase C (PKC) is a family of serine/threonine kinases. They have
important role in regulating a range of cellular functions including gene expression,
differentiation, proliferation, cell cycle, apoptosis and cell migration. The PKC
family includes 12 isoenzymes that can be divided into three groups depending on
activation requirements. Conventional PKCs are calcium dependent and they
require negatively charged phospholipid and diacylglycerol for activation. Novel
PKCs are calcium independent, as conventional PKCs their activation requires
phospholipid and diacylglycerol. Atypical PKCs are both calcium and diacylglycerol
independent protein kinase group [136].
Regarding the PKC as a receptor for tumor-promoting phorbol esters, the
researcher targets PKC for the potential treatment of cancer.
PKC is activated by phorbol esters and this event prevents cell death. Therefore,
the inhibition of PKCα results in apoptosis. PKC activity has been reported to
increase in many types of cancer, suggesting that PKC has important role in tumor
formation. There are many PKC inhibitor candidates in clinical development for the
treatment of cancer (Figure 2) [137].
First class of PKC inhibitors with anti-cancer activity are bryostatins. They are
macrocyclic lactones extracted form marine bryozoan Bugula nerutina. Interaction
of bryostatins with regulatory domain of PKC causes downregulation of the
enzyme. Besides anti-proliferative, apoptotic and cytotoxic effects of Bryostatins on
cancer cells, they also have immunomodulatory functions. Bryostatins provide the
development of tumor-specific cytotoxic T-lymphocytes and stimulates the release
of different cytokines such as TNF, IL-6. Both the immunomodulatory effect and
downregulation of PKC has participated in antitumor effect of bryostatins
[137, 138].
Second class of PKC inhibitors are staurosporines. Staurosporine is a microbial
alkaloid derived from Streptomyces species organisms. In addition to PKC,
staurosporine has shown the activity aganist different kinases including, pyruvate
dehydrogenase kinase 1 (PDK1), PKA and PTK. Several staurosporines are under in
clinical research such as UCN-01 (7-hydroxystaurosporine) or midostaurin (N-
benzoyl staurosporine, PKC412) [138]. UCN-01 (7-hydroxy-staurosporine) has
been reported to have more PKC inhibitory effects than staurosporine [105, 137].
UCN-01 causes cell cycle arrest in G1 step, thus leading the cell to death.
There is a growing interest in antisense therapy for PKC inhibitors. The struc-
tures of PKC inhibitors are shown in Table 5. ISIS 3521, an antisense therapy agent,
is a phosphorothioate antisense oligodeoxynucleotide. ISIS 3521 binds to 30
untranslated region (UTR) of human PKC-α messenger RNA (mRNA). This
hybridization is then cleaved by RNase H and resulted in inhibition of PKC-α
expression. Based on in vitro and in vivo studies results, ISIS 3521 may be a potential
treatment agent for cancer patients [139].
Besides PKC inhibitor classes for cancer therapies described above, there are
other agents including safingol, quercetin, antiestrogens, and miltefosine. Safingol
is a synthetic sphingoid base analogue and safingol was the first to enter clinical
trials. Quercetin belongs to flavonoids and widely distributed in nature. Quercetin
inhibits different classes of protein kinases including PKC, phosphatidyl inositol-3
kinase. The PKC inhibitory effect of the classical antagonism of estradiol at the
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estrogen receptor level has been mentioned in many studies. However, the
antiestrogen tamoxifen and its analogues have also been shown to inhibit PKC at
very low concentrations. Miltefosine is an alkylphosphocholine and it shows its
activation by preventing phospholipid metabolism. Miltefosine’s antitumor activity
is possibly associated with its abilitiy to inhibit PKC, but there has also been multi-
ple alternative actions [137].
Although most protein kinase C inhibitors target the PKC-α, inhibitors targeting
PKC-β have been investigated. PKC-β belongs to major PKC isoform classes.
Hyperglycemia activated PKC-β leads to diabetic kidney diseases. LY333531 named
as Ruboxistaurin selectively inhibits PKC-β. Recent studies showed that LY333531
significantly reduced PKC activity and PKC-β protein expression in the kidney
[140, 141].
7. Conclusions
Protein kinases are potent oncogenes because of their ability to activate or
inhibit other proteins. Furthermore, the ability to activate other protein kinases
results in producing an exponential signal. In other words, a tiny signal can lead to a
huge cellular response. This property of protein kinases makes their strict regulation
crucial, and any dysregulation can lead to catastrophic outcomes. Many cancers are
caused by the dysregulation of such oncogenic kinases, and inhibitors of those
shown to increase overall survival in cancer patients. Although some tumors may
gain resistance to some of those protein kinase inhibitors (PKIs), promising results
of PKI administered cancer patients have led to developing new PKIs to treat
PKI-related cancers [142].
Target Inhibitors




Structures of other kinases’ inhibitors.
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